QBTS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
QBTS is not a good immediate buy for a Beginner with a long-term focus and $50,000-$100,000 to invest. The stock has strong growth catalysts and bullish analyst support, but the current pre-market pullback, elevated option activity, and near-term overbought technicals make this a hold rather than an urgent buy right now. Because the investor is impatient and does not want to wait for an optimal entry, I would still not call this a clean buy at the current price.
QBTS is in a short-term upward trend but looks stretched. MACD is positive and expanding, which supports momentum. However, RSI_6 at 73.389 suggests the stock is near overbought conditions despite being labeled neutral in the provided data. Moving averages are converging, which often signals a transition phase rather than a clear breakout continuation. The pre-market price is 28.8, down 2.34%, while key resistance sits at 29.671 (R1) and 32.931 (R2). That means the stock is trading just below nearby resistance after a strong run, making upside harder to chase immediately. The similar-pattern outlook also points to weak near-term returns, with estimated downside over the next week and month.
["U.S. government plans to invest up to $100 million each in D-Wave, Rigetti, and Infleqtion, which is a major sector catalyst.", "Q1/Q4-related news shows revenue growth of 179% year over year to $24.6 million in FY 2025.", "Bookings surged and management raised system sales cadence from one per year to 2-3, implying improving commercial traction.", "D-Wave has over 135 commercial customers, including Pfizer and Mastercard, supporting real customer adoption.", "Analysts at Canaccord, Mizuho, and Jefferies kept bullish ratings and maintained or only modestly reduced price targets.", "MACD remains positive and expanding, showing momentum is still intact."]
["Pre-market price is down 2.34%, showing immediate selling pressure.", "RSI is elevated, suggesting the stock may be extended after its recent move.", "Nearby resistance at 29.671 may cap upside in the very short term.", "The company still posted a large net loss of $355.1 million in FY 2025.", "The accumulated deficit is near $1 billion, which highlights ongoing financial strain.", "Recent news noted executives across quantum names sold significantly more stock than they bought over five years, which can weigh on sentiment.", "No strong insider buying, hedge fund accumulation, or congress trading support is available.", "Historical pattern data suggests weak next-week and next-month performance."]
The latest reported season is FY 2025, and the company delivered strong top-line growth with revenue of $24.6 million, up 179% year over year. That is a meaningful acceleration in demand. However, profitability remains a major weakness, with a net loss of $355.1 million. The company is growing fast but is still far from earnings stability, so the financial picture is improving on revenue but remains speculative on the bottom line.
Wall Street remains mostly positive, but target cuts show some caution. Canaccord lowered its target to $41 from $43 and kept Buy. Mizuho cut its target to $29 from $31 and kept Outperform. Jefferies maintained Buy with a $45 target and said the setup is attractive after Q1, citing bookings, a scalable dual-platform roadmap, and multiple growth vectors. Northland was more conservative with Market Perform and a $22 target. Overall, the pros view is constructive because of growth, bookings, and system sales momentum, but the cons view is that valuation, competition, and execution risk remain significant.
